---
title: "Inventiva S.A. (IVA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/IVA.US.md"
symbol: "IVA.US"
name: "Inventiva S.A."
industry: "Biotechnology"
---

# Inventiva S.A. (IVA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [inventivapharma.com](https://inventivapharma.com) |

## Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxi...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 219 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -8.31% |  |
| Net Profit YoY | -205.39% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -123.31 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.29B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 18.72M |  |


**Multi Score**: D

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 707.22% | A |
| Profit Margin | -1833.03% | E |
| Gross Margin | 100.96% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -8.31% | D |
| Net Profit YoY | -205.39% | E |
| Total Assets YoY | 395.98% | A |
| Net Assets YoY | 87.69% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -5.46% | D |
| OCF YoY | -8.31% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.16 | D |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 104.98% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Inventiva S.A.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "707.22%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-1833.03%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.96%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-8.31%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-205.39%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "395.98%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "87.69%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-5.46%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-8.31%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.16",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "104.98%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.75 | 336/604 | - | - | - |
| PB | -123.31 | 553/604 | - | - | - |
| PS (TTM) | 68.70 | 242/604 | 48.71 | 31.53 | 23.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 10 | 83% |
| Overweight | 2 | 17% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.72 |
| Highest Target | 26.00 |
| Lowest Target | 8.80 |

## References

- [Company Overview](https://longbridge.com/en/quote/IVA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/IVA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/IVA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.